boceprevir (Victrelis)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

Adverse effects

Drug interactions

Mechanism of action

More general terms

References

  1. Poordad F et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011 Mar 31; 364:1195 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21449783
  2. Bacon BR et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011 Mar 31; 364:1207 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21449784
  3. Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med 2011 Mar 31; 364:1272 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21449791
  4. FDA NEWS RELEASE: May 13, 2011 FDA approves Victrelis for Hepatitis C http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm
  5. Prescriber's Letter 18(8): 2011 Victrelis (Boceprevir) and Incivek (Telaprevir) for Hepatitis C Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270802&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. 6.0 6.1 FDA MedWatch April 26, 2012 Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication - Drug Interactions http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm291144.htm

Database